Welcome to our dedicated page for Calidi Biotherapeutics SEC filings (Ticker: CLDI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Calidi Biotherapeutics filings document a biotechnology issuer developing targeted genetic medicines through its RedTail virotherapy platform and related oncology candidates. The company’s common stock trades on NYSE American under CLDI, and its reports describe operating updates, financial results, regulatory communications, and corporate presentations tied to its pipeline.
Recent SEC disclosures include Form 8-K reports on material agreements, public and private equity transactions, common stock units, pre-funded warrants, common stock warrants, and Regulation FD materials. Proxy filings document annual-meeting matters, director elections, board composition, committee assignments, auditor ratification, stockholder voting mechanics, and other governance subjects.
Calidi Biotherapeutics, Inc. filed its annual report for the year ended December 31, 2025, outlining a high-risk biotech profile focused on oncolytic virus cancer therapies. The company has no approved products, has not generated revenue from product sales, and has incurred significant operating losses.
Management discloses it has insufficient cash to continue operations for the next 12 months, creating substantial doubt about its ability to continue as a going concern and a need for substantial additional funding. Calidi’s lead RedTail candidate, CLD-401, is planned for a first-in-human Phase 1 trial by the end of 2026, while CLD-201 (SuperNova) has an approved IND and FDA Fast Track Designation for soft tissue sarcoma, and CLD-101 (NeuroNova) is in early-stage glioma trials run by academic partners.
Calidi Biotherapeutics filed an 8-K to furnish its fourth quarter and full-year 2025 results and recent developments. For 2025, the company reported a net loss attributable to common stockholders of $25.6 million, or $5.95 per share, compared with $23.8 million, or $35.70 per share, in 2024.
Research and development expenses were $9.7 million and general and administrative expenses were $10.5 million for 2025, slightly shifting from 2024 levels. Calidi ended 2025 with $5.6 million in cash and $0.2 million in restricted cash, down from $9.6 million and $0.2 million a year earlier.
Operationally, the company highlighted progress on its RedTail platform and lead candidate CLD-401, which is in IND-enabling studies targeting several solid tumors. It received FDA Type D feedback, plans to file an IND by the end of 2026, established manufacturing partnerships, presented new in situ T-cell engager data, and raised $6.5 million through a public offering and at-the-market sales.
Calidi Biotherapeutics completed an underwritten public offering of 2,278,731 common stock units and 9,815,900 pre-funded warrant units, generating gross proceeds of approximately $6.03 million before fees. Each unit includes common stock or a pre-funded warrant plus three series of common stock warrants with initial exercise prices of $0.50 per share and staggered terms of six months, one year, and five years, all immediately exercisable and featuring exercise-price reset provisions.
The underwriter also received a warrant to purchase up to 604,732 common shares at $0.625, expiring in 2031. Calidi agreed to short-term restrictions on issuing additional equity or variable-rate financing and its directors and officers agreed to 90-day lock-ups. The company amended existing Series G, H, and I warrants so their exercise prices are reduced to $0.50 per share, while other terms remain unchanged. As of March 11, 2026, Calidi had 10,545,725 common shares outstanding, including 150,000 non-voting shares held in escrow.
Calidi Biotherapeutics, Inc. received a new Schedule 13D disclosure from investor Ognian Anguelov Gavrilov. He reports beneficial ownership of 700,000 shares of Calidi common stock, representing 9.8% of the outstanding class. The filing states the shares were acquired with personal funds for investment purposes.
The investor has sole voting and dispositive power over all 700,000 shares and no other person has rights to dividends or sale proceeds. The filing notes he may buy more shares or sell some or all of his holdings over time but currently has no specific plans for corporate actions involving Calidi.
Calidi Biotherapeutics, Inc. is offering up to 703,731 Common Stock Units in a firm‑commitment underwriting, each Unit priced at $0.50 and consisting of one share of Common Stock plus three series warrants (Series J, K and L). The offering also permits up to 9,815,900 Pre‑Funded Warrant Units to avoid >4.99% beneficial ownership limits.
The Units carry Common Warrants exercisable at $0.50 with varying terms (Series J: 5 years; Series K: 1 year; Series L: 6 months) and reset mechanics after the 45th calendar day. Net proceeds are estimated at approximately $4.5 million (before over‑allotment) to be used for working capital and general corporate purposes. The prospectus notes a going concern qualification and preliminary unaudited year‑end cash of $5.6 million.
Calidi Biotherapeutics, Inc. is conducting a firm-commitment public offering of Common Stock Units and, for certain purchasers, Pre-Funded Warrant Units, each unit including one share (or pre-funded warrant in lieu of a share) and one each of Series J, Series K and Series L warrants.
The Common Warrants include reset provisions at the 45th calendar day and after a reverse split approved and effective during fiscal 2026; exercise limitations include a 4.99% beneficial ownership cap (expandable to 9.99% at holder election). The company notes a 1-for-12 reverse stock split effected August 4, 2025 and lists NYSE American symbol CLDI. Management discloses substantial doubt about the company’s ability to continue as a going concern and preliminary cash of $5.6 million as of December 31, 2025.
Calidi Biotherapeutics, Inc. investor Lincoln Alternative Strategies LLC filed an amended Schedule 13G to report that it no longer beneficially owns any shares of Calidi common stock. The filing shows 0 shares with 0% of the class, with no sole or shared voting or dispositive power.
The amendment reflects ownership of 5 percent or less of the common stock, par value $0.0001 per share, of Calidi Biotherapeutics. Lincoln Alternative Strategies is organized in Delaware, and the certification states the securities were not acquired to change or influence control of the company.
Calidi Biotherapeutics, Inc. filed a current report to note that it has made an updated corporate presentation available on its website. The presentation is included as Exhibit 99.1 and is furnished under Regulation FD, meaning it is provided for informational disclosure and is not deemed filed for liability purposes under the Exchange Act or automatically incorporated into other securities law filings.
Ognian Anguelov Gavrilov has filed a Schedule 13G reporting a significant passive ownership stake in Calidi Biotherapeutics, Inc. common stock. He reports beneficial ownership of 560,000 shares of Calidi’s common stock, representing 7.78% of the class as of the reported date.
Gavrilov, a U.S. citizen, has sole voting and sole dispositive power over all 560,000 shares, with no shared voting or dispositive authority and no group membership. The filing states this is a first-time Schedule 13G submission and notes that it was made late due to an inadvertent oversight. He certifies that the shares were not acquired and are not held for the purpose of changing or influencing control of Calidi.
Calidi Biotherapeutics, Inc. filed a current report describing a new press release that shares corporate updates for the fiscal year ended December 31, 2025 and outlines key operational plans for 2026. The release also includes preliminary, unaudited financial information that is still subject to completion of year-end closing and audit procedures.
The company highlights forward-looking plans, including its intention to submit an Investigational New Drug application by the end of 2026. All preliminary figures may change once the audit is completed, and the information in this report is furnished rather than filed for securities law purposes.